Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia
AUTOR(ES)
Viana, Simone Santana, Araujo, Gustavo Santos, Faro, Gustavo Baptista de Almeida, Cruz-Silva, Lana Luíza da, Araújo-Melo, Carlos André, Cipolotti, Rosana
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2012
RESUMO
OBJECTIVE: To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after vaccine booster doses. METHODS: Antibody levels against hepatitis B, rubella, measles and mumps vaccine antigens were evaluated in 33 children after completing chemotherapy (before and after vaccine booster doses) and the results were compared to the data of 33 healthy children matched for gender, age and social class. RESULTS: After chemotherapy, 75.9%, 67.9%, 59.3% and 51.7% of the patients showed low antibody titers that would be unlikely to protect against exposure to measles, rubella, hepatitis B and mumps, respectively. After receiving a vaccine booster dose for these antigens the patients had high antibody levels consistent with potential protection against measles, mumps and hepatitis B, but not against rubella. CONCLUSION: Extra doses of measles-mumps-rubella plus hepatitis B vaccines are recommended in acute lymphoblastic leukemia patients submitted to treatment after hematologic recovery. After this, viral vaccine antibody levels should be verified to define the individual's protective status.
Documentos Relacionados
- Differential Immune Responses to Primary Measles-Mumps-Rubella Vaccination in Israeli Children
- Immunity against hepatitis B and measles vaccination after chemotherapy for acute lymphoblastic leukaemia in children: revaccination policy
- The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales
- ANTIBODIES VIRAL VACCINES IN CHILDREN ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CHEMOTHERAPY
- Clinical and laboratorial aspects of aseptic meningitis associated with MMR (measles-mumps-rubella) vaccine at a referral hospital in the State of Bahia